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Abstract 
 
Background 
Impulsivity is poorly planned, premature or inappropriate behaviour, and deficits in impulse 
control are linked to a number of neuropsychiatric disorders. There are a number of 
theories relating to the neural basis of impulsivity, but the precise molecular mechanisms of 
impulse control are not clearly understood. Motor impulsivity has been observed in adult 
zebrafish, but in order to increase throughput it would be beneficial if early markers could 
be identified in larvae. One such method was recently shown to have some potential 
efficacy in zebrafish larvae, relating to an ADHD morphant (lphn3.1) showing increases in 
motor ‘peaks’ during free swimming behaviour.  
 
Objective 
The aim of this study was to carry out a pharmacological evaluation of motor ‘peaks’ as a 
measure of motor impulsivity in larval zebrafish, as well as evaluate the behaviour of 
mutant lines that might be predicted to show variation in motor impulsivity. 
  
Method 
6dpf zebrafish larvae were filmed for 90-seconds following incubation in amisulpride (a 
DRD2/3 antagonist), nicotine, apomorphine (a non-specific dopamine agonist), atomoxetine 
(a norepinephrine reuptake inhibitor), and methylphenidate (a combined 
dopamine/norepinephrine agonist). We also filmed 6dpf larvae homozygous and 
heterozygous for mutations in pink1, disc1, and ache. In all larvae, we analysed distance 
moved and motor ‘peaks’, calculated as number of 3-second bins in which the larva traveled 
> 10mm.  
 
Results 
Atomoxetine and methylphenidate, which reduce impulsivity in humans and other 
mammalian models, reduced motor peaks while having no effect on overall distance 
traveled. Apomorphine increased locomotor peaks in a bimodal manner. disc1 homozygous 
mutants showed lower peaks than wild-type siblings. Finally, although nicotine increased 
distance traveled, there were no effects on motor peaks.    
 
Conclusion 
The results suggest that analysis of motor peaks may be a promising method for the early 
detection of impulsivity-related phenotypes. 
 
 
Keywords: zebrafish; motor impulsivity; apomorphine; disc1; methylphenidate; atomoxetine 
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Impulsivity is characterized as behavior that is poorly planned, premature or inappropriate 
to the context in which it is performed (1). Impulsivity can be operationally defined as 
reduced ‘self-control’ (e.g., choosing a relatively higher value reward after a delay over a 
relatively lower, more immediate reward (2)), or as a reduced ability to inhibit a pre-potent 
response (e.g., as measured by ability to withhold responding during a pre-stimulus interval 
on a continuous performance task (3)). The inability to withhold a pre-potent response, or 
‘motor’ impulsivity (4), is an important behavioral predictor of a number of neuropsychiatric 
disorders, such as attention deficit-hyperactivity disorder (ADHD; (5)), personality disorders 
(6), mania (7), substance abuse disorders (8) and eating disorders (9). Thus, understanding 
the molecular and cellular basis of impulsivity is a priority in biological psychiatry in order to 
improve treatments (10).  
 
Recently, zebrafish have proved useful as an animal model of impulsivity. For example, 
Parker and colleagues have found evidence for motor impulsivity in a zebrafish version of 
the 5-choice serial reaction time task (5CSRT (11, 12)), the ‘gold-standard’ test for motor 
impulsivity in rodents (13). During the 5CSRT, the animal is required to continuously monitor 
which one of five stimuli are presented following a delay (a pre-stimulus interval; PSI) in 
order to receive a food reinforcer. Impulsivity can be operationally defined in the context of 
this task by the inability to withhold responding during the PSI. We demonstrated that  
motor impulsivity may be controlled by noradrenergic circuits in zebrafish (14), as is the 
case in rodents (15) and humans (16), with all of these species showing a dose-dependent 
reduction in impulsivity following administration of the noradrenergic reuptake inhibitor, 
atomoxetine. The effects we observed were in adult (3 months post-fertilization) zebrafish. 
Adult zebrafish represent a refined model system for the study of the molecular basis of 
disease over rodents, in particular owing to their small size and high reproductive rate, but 
also their genetic tractability and resilience to mutation (17). Indeed, we recently 
demonstrated that zebrafish heterozygous for a null mutation in the acetylcholinesterase 
gene showed lower levels of impulsivity in our 5CSRT test (18).  
 
 
An alternative method of quantifying impulsivity in zebrafish larvae was proposed by Lange 
and colleagues, in a study of the behavioral and morphological effects of mutation in a gene 
that has been linked strongly to ADHD, latrophilin 3 (LPHN3) (19). Their method involved 
filming 6-day-post-fertilization (6dpf) larvae for 90 seconds and observing their movement 
patterns. Interestingly, as well as generally being more hyperactive, the lphn3 morphant 
showed idiosyncratic motor ‘peaks’, which the authors suggested may represent motor 
impulsivity. It may be, therefore, that larvae could show early signs or behavioral markers of 
impulsivity. Zebrafish larvae are of significant benefit as a model system for the drug 
exposure on account of their potential for setting up high-throughput screens. Thus if we 
are able to identify early larval markers of impulsivity, this would increase the efficacy of 
testing novel pharmacotherapeutics for impulsivity-related neuropsychiatric disorders.  
 
The aim of the current study was to examine the utility of larval measures of impulsivity. 
The objectives were first to carry out a pharmacological validation using drugs that would be 
hypothesized to increase impulsivity (DRD2/D3 receptor antagonist amisulpride, the non-
specific DA agonist apomorphine, and the nAChR agonist nicotine), followed by impulsivity-
reducing drugs (methylphenidate and atomoxetine). The second phase of the study was to 
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examine the performance on this task of genetic lines that have previously been shown to 
have variability in impulsivity in zebrafish, ache(18). We also hypothesized that there might 
be differences in mutant lines where the mutated genes had previously been linked to 
impulsivity in other species. These lines included ache (18), but also disc1 (20), a putative 
model of schizophrenia, and pink-1 (21), a putative model of Parkinson’s disease. Both 
PINK1 (22) and DISC1 (23) have been linked to increased impulsivity in previous studies. 
   
Materials and methods 
 
Subjects 
 
Zebrafish larvae were bred in the aquarium facility at Queen Mary University of London 
according to published protocols (24). Larvae were grown in Petri dishes to 6dpf in an 
incubator (28oC) prior to testing. Care was taken to ensure that larvae used for testing were 
of a similar size and developmental period as this would have a major impact upon 
performance on the locomotor tasks. Prior to testing, larvae were pipetted carefully out of 
their petri dishes and placed in the testing plates in 2ml of aquarium water. The following 
mutant lines were acquired from ZIRC (www.zebrafish.org). achesb55/+ were acquired as 
heterozygote outcrosses. Because ache-/- are not viable, we were only able to examine the 
larvae from ache+/- incrossed adults. This would result in 67% ache+/- in the sample (and 33% 
ache+/+ ; ache -/- is homozygous lethal by day 6). pink1-/- were bred by in-crossing 
homozygote siblings, and heterozygotes were bred by crossing pink1-/- with wild-type (TU) 
siblings. disc1fh292/fh292 were acquired as heterozygote outcrosses. disc1-/- were bred by in-
crossing homozygote siblings, and heterozygotes were bred by crossing disc1-/- with wild-
type (TU) siblings.  
 
 
Materials 
 
Larvae were filmed in a custom-made larval filming tower (Fig 1; TrackSys, Nottingham, UK), 
which integrated with Ethovision XT software (Noldus Information Technology, 
Wageningen, Netherlands). During filming, larvae were placed in clear 12-well-plates, with 
one larva/well. Each well contained 2ml aquarium water (24oC).  
 
Drugs 
 
Drugs were dissolved in aquarium water as a stock solution (except amisulpride; see below), 
and added to the individual wells of the plate prior to filming the fish. Drugs used were 
amisulpride (Tocris Bioscience, UK), nicotine hydrogen tartrate (Sigma, UK), apomorphine 
(Sigma, UK), methylphenidate hydrochloride (Sigma, UK), and atomoxetine hydrochloride 
(Sigma, UK). All drugs were first made into stock solutions (in aquarium H2O) stocks through 
serial dilution to reach concentrations that allowed for 100µl of stock to be added to 2ml 
H2O to reach the required well concentration. This ensured that the same volume of 
solution was added to each well containing a larva. Amisulpride was a solid, and 8mg was 
initially dissolved in 1ml 100% DMSO. This was then added to 200ml H20. These stock 
solutions were added to aquarium-treated water to create a diluted stock solution to add to 
the wells in 100µl aliquots. For the amisulpride-treated larvae, all solutions were made up to 
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give a final concentration of 0.0025% DMSO - that required for the highest amisulpride 
dose. 
 
 
 
Fig 1. Illustration of larval filming tower for tracking movement of zebrafish. This comprised 
a camera, IR filter, IR array and a 12-well plate. 
 
 
Behavioral recording and peak analysis 
 
Larvae were first habituated for 90-seconds, and then filmed for 90-seconds, in accordance 
with previous work (19). For drug trials, the initial 90-seconds constituted the incubation 
period in the drug. This incubation time was based on previous work with zebrafish larvae 
and locomotor responses to nicotine; Pezhold and colleagues found that zebrafish larvae 
respond to nicotine after 30-seconds incubation in the drug (25), thus 90-seconds appeared 
to be sufficient to allow uptake of the drug. However, for amisulpride, because there was no 
measureable difference after 90-sec incubation, we also incubated for 30-min to ensure 
sufficient time for uptake. Movement data, including distance travelled (mm) were collected 
in Ethovision XT. Peaks were defined as movements of >10mm in 3-seconds of filming. 
Specifically, all distance data was outputted by Ethovision in 3-second time bins. Once all 
the data were collected, we created a list of every 3-second bin and calculated the mean 
distance, as well as the maximum distance (Max) for each larva. We then subtracted the 
mean overall distance for each 3 min from the mean value of Max, giving a total value of 
10.8mm. We therefore set the value for a burst of movement as >10mm in 3 seconds. The 
total number of peaks for each larva was then ascertained, as was the total distance moved 
over the 90-seconds of filming.  
 
Data analysis 
 
All distance data were analyzed using a fixed-effects univariate analysis of variance 
(ANOVA), with the dependent variable distance (mm) and the independent variable either 
dose (for the drugs used) or genotype. The only exception was achesb55/+ which was 
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analyzed using a t-test. After fitting all models, residuals were checked for Gaussian error 
structure. Motor impulsivity was measured using an analysis of the number of ‘peaks’ for 
each fish. The errors were Poisson distributed (count data) and thus the peaks were 
analyzed using a Generalized Linear Model with a Poisson distribution (log link). Again, the 
independent variable was either dose (for drugs) or genotype. 
 
Results 
 
Can motor impulsivity be induced pharmacologically? 
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Fig. 2. Dose-dependent effects of amisulpride (DRD2/D3 antagonist[a,b]), nicotine [c,d] and 
apomorphine (non-selective dopamine agonist [e,f]) on distance traveled and motor peaks. 
**P < 0.01 
 
To examine if motor impulsivity could be induced pharmacologically, we chose three drugs, 
amisulpride, nicotine and apomorphine. Amisulpride is a selective dopamine receptor (DR) 
D2/D3 sub-type antagonist. As reduction in DRD2 is associated with increased impulsivity in 
rodents (26), we reasoned that if our procedure was probing motor impulsivity, 
pharmacological blockade of D2/D3 receptors would increase peaks in a dose-dependent 
manner. Figure 2a displays the distance traveled as a function of dose of amisulpride. There 
was no significant effect of amisulpride on distance traveled, F < 1. Figure 2b displays the 
numbers of peaks as a function of dose of amisulpride. A generalized linear model showed 
no overall effect of dose on peaks, 2 = 8.8, df = 4, P = 0.07. Collectively, these data suggest 
that amisulpride does not affect larvae at the doses tested here. It is possible that the 
reason that we did not observe an effect on locomotor behaviour was the result of 
insufficient incubation time. Indeed, a previous study with adult zebrafish incubated the 
animals for 30-min (27). Thus we incubated the larvae in 0, 0.13 and 0.5mg/l amisulpride for 
30-min prior to filming as a comparison. The results were very similar to 90-sec incubation. 
There was no effect of dose of amisulpride on distance traveled in the 90-sec filming (0mg/l 
= 589.39±39.4mm; 0.13mg/l = 642.29±38.9mm; 0.5mg/l = 666.24±38.9), F (2,140) = 1.01, P = 
0.37. In addition, there was no effect of dose of amisulpride on number of peaks during the 
90-sec filming (0mg/l = 6.06±0.36; 0.13mg/l = 6.17±0.36; 0.5mg/l = 6.88±0.38), 2  = 2.89, df 
= 2, P = 0.24. 
 
The second drug tested was nicotine. Acute nicotine is known to increase impulsivity in rats 
through activation of nAChR 42 (28). Figure 2c displays the distance traveled as a 
function of nicotine dose. A univariate fixed-effect ANOVA revealed that there was a main 
effect of dose on distance traveled, F (4,198) = 7.3, P < 0.001. Post-hoc Tukey HSD tests 
revealed the differences were between the control (0µM) and 3µM, 6µM and 12µM doses 
(Ps < 0.001). There was no difference between distance traveled in the 0µM and 1.5µM 
doses (P = 0.5). Figure 2d displays the number of peaks as a function of dose of nicotine. A 
generalized linear model revealed no overall effect of dose on peaks, 2  = 6.5, df = 4, P = 
0.17. Previous studies had shown that nicotine is behaviourally activating after an 
incubation time of 30-sec (25), and we observed a dose-dependent effect on locomotor 
responding of the drug, thus we did not incubate for longer as a comparison for this drug.  
 
Finally, we examined the effects of the non-selective dopamine agonist, apomorphine. 
Apomorphine is a non-selective dopamine agonist. It is known to activate both D2 and, to a 
lesser extent, D1 receptors. It has also been shown to act as an antagonist of 5-HT2 and α-
adrenergic receptors, both with high affinity (29). Figure 2e displays the distance traveled as 
a function of apomorphine dose. A univariate fixed-effect ANOVA revealed no main effect of 
dose on distance traveled (F < 1). Figure 2f displays the number of peaks as a function of 
dose of apomorphine. A generalized linear model revealed a main effect of dose on peaks, 
2  = 168.6, df = 3, P < 0.001, with more peaks at 7µM (P < 0.001) and 37µM (P < 0.001) as 
compared to 0µM control. There was no difference between control and 18µM, however, 
suggesting a bimodal dose-activating effect of the drug on locomotor peaks. 
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What is the effect of drugs that have therapeutic efficacy in the treatment of impulsivity on 
motor peaks? 
 
 
 
 
Fig. 3. Dose dependent effects of atomoxetine on reducing (a) distance traveled and (b) 
motor peaks. *P ≤ 0.05 
 
We examined if atomoxetine, a norepinephrine reuptake inhibitor that reduces impulsivity 
in humans (30), rodents (31) and recently, adult zebrafish (32), affected distance traveled 
and peaks in larvae. We chose three doses of atomoxetine (0µM, 1µM and 2µM). Figure 3a 
displays the dose-dependent effects of atomoxetine on distance traveled (mm). A univariate 
ANOVA revealed a no significant main effect of atomoxetine on distance traveled, F (2,125) 
= 1.89, P = 0.16. Figure 3b displays the dose-dependent effect of atomoxetine on the 
number of peaks. A generalized linear model revealed a main effect of atomoxetine, 2  = 
6.24, df = 2, P = 0.044, with 2µM atomoxetine reducing peaks relative to 0µM (P = 0.03) and 
1µM (P = 0.03). There was no difference between 0µM and 1µM (P = 0.96). 
 
 
 
Fig 4. Dose dependent effects of methylphenidate on reducing (a) distance traveled and (b) 
motor peaks. *P ≤ 0.05 
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Next we examine the effects of methylphenidate, a combined dopamine/noradrenaline 
reuptake inhibitor used that reduces impulsivity in humans (33) and rodents (34), on peaks 
and distance in larval zebrafish. Again, we chose three doses of methylphenidate (0µM, 
7.5µM and 15µM). Figure 4a displays the dose-dependent effects of methylphenidate on 
distance traveled (mm). A univariate ANOVA revealed no significant main effects of 
methylphenidate on distance traveled (F < 1). Figure 4b displays the dose-dependent effect 
of methylphenidate on the number of peaks. A generalized linear model revealed a main 
effect of methylphenidate, 2  = 6.26, df = 2, P = 0.04, with more peaks at 15µM than at 0µM 
(P = 0.013) and at 7.5µM (P = 0.03). There was no difference in peaks between 0µM and 
7.5µM atomoxetine (P = 0.74).  
 
Collectively, these data suggest that although there is a dose-dependent effect on 
movement by nicotine, there is no effect on motor impulsivity as operationally defined 
through number of peaks.  In addition, both atomoxetine and methylphenidate dose-
dependently reduced peaks, but not distance traveled. 
 
Can motor impulsivity be measured in mutant lines? 
 
To examine if larval motor peaks could be a potential marker for adult impulsivity, we tested 
three mutant lines with either hypothesized (disc1, pink1) or previously demonstrated 
(ache) differences in impulsivity. Fig 5a displays the distance traveled during 90-sec filming 
of disc1 heterozygous (+/-), homozygous (-/-) and wild-type siblings (+/+). A univariate ANOVA 
revealed that there was no significant effect of mutation on distance, F (2,82) = 1.87, P = 
0.17. Fig 5b displays the number of peaks during the 90-sec filming for disc1 -/-, +/- and +/+. A 
generalized linear model revealed a significant main effect of mutation on peaks, 2  = 8.38, 
df = 2, P = 0.015, with disc1-/- larvae having significantly fewer peaks than disc1+/+ siblings (P 
< 0.01). Although disc1+/- larvae appeared to have fewer peaks than disc1+/+, this was not 
statistically significant (P = 0.08). Fig 5c displays the distance traveled during 90-sec filming 
of pink1 -/-, +/-, and +/+ wild-type siblings. A univariate ANOVA revealed no significant effect of 
mutation on distance (F < 1). Fig 5d displays the number of peaks during the 90-sec filming 
for pink1-/-, +/- and +/+ siblings.  A generalized linear model revealed no significant main effect 
of mutation on peaks, 2  = 2.77, df = 2, P = 0.25. Fig 5e displays the distance traveled during 
90-sec filming of ache+/- incrossed (ache -/- are non-viable at 6dpf) and ache+/+ -incrossed 
siblings. A between-subjects t-test revealed that ache+/- in-cross larvae traveled significantly 
less distance than ache+/+ siblings, t (262) = 3.99, P < 0.001. Fig 5f displays the number of 
peaks during the 90-sec filming for ache+/- incross and ache+/+ siblings. A generalized linear 
model revealed no significant effect of mutation on peaks, 2  = 1.82, df = 1, P = 0.18. 
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Fig 5. Dose dependent effects of disc1 (a, b), pink1 (c, d) and ache (e, f) mutations on 
distance traveled (left column) and motor peaks (right column). **P < 0.01 
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Discussion 
 
The aim of this study was to examine the utility of motor ‘peaks’ a putative measure of 
motor impulsivity for larval zebrafish. The method was based on a previous report of motor 
impulsivity in a morpholino oligo morphant zebrafish harboring a knockdown of lphn3.1, a 
model for ADHD (19). We carried out both a pharmacological examination and an 
examination of mutant lines that would be expected to show differences in motor 
impulsivity. The results suggested that there may be some merit in this method for 
detecting early markers for variability in impulse control. Most importantly, we observed 
that drugs that reduce impulsivity in rodent models and humans, atomoxetine and 
methylphenidate, dose-dependently decreased motor peaks, but had no effect on distance 
traveled. We found that incubation in nicotine (nAChR agonist) or amisulpride (dopamine 
DRD2/D3 antagonist), despite showing differences in movement (in the case of nicotine), 
showed no signs of motor impulsivity, as operationalised by increases in motor peaks. 
However, we found that incubation in apomorphine (a non-selective dopamine agonist) 
increased peaks in a bimodal fashion, but had no effects on total distance traveled. Finally, 
we found that although ache+/- incrossed larvae showed lower movement than ache+/+ 
incrossed siblings, there were no measureable differences in motor peaks. By contrast, 
disc1-/- showed reductions in motor peaks as compared to wild-type siblings but no changes 
in movement, suggesting reduced motor impulsivity. There were no observable differences 
in pink1-/-. 
 
In both human (35) and adult laboratory rats (36, 37) and zebrafish (19, 32), atomoxetine 
dose-dependently reduces impulsivity. Here, at similar doses to our previous findings in 
adults zebrafish (32), we observed a reduction in motor peaks at 2µM doses. We did not see 
any corresponding reductions in total distance travelled. Atomoxetine is a selective 
noradrenaline reuptake inhibitor (29) used commonly to treat symptoms of ADHD (30), and 
impulsivity and hyperactivity in other neuropsychiatric disorders (38, 39). Atomoxetine 
increases pre-frontal cortical noradrenaline and dopamine, and this is hypothesised to be 
the mechanism by which the drug reduces impulsivity: i.e., by increasing executive control 
over behaviour (29, 40). In addition, recent evidence has suggested that this may be the 
effect of atomoxetine decreasing the tonic firing rate of locus coeruleus neurons while 
simultaneously increasing both the excitatory and inhibitory responses to external stimuli 
(41). These data suggest that atomoxetine increases the phasic:tonic ratio of locus coeruleus 
neurons, thus increasing the ‘signal to noise ratio’, and potentially enhancing cognition. In 
zebrafish, noradrenergic neurons in the locus coeruleus have been detected from early in 
brain ontogeny (42, 43), and alpha-2 adrenergic (adra2a) receptors expression is present in 
telencephalic cells (44) where there are high concentrations of dopamine cells in zebrafish 
(45). In addition, Lange et al (19) demonstrated that atomoxetine rescued behavioural 
hyperactivity phenotype in lphn3.1 knock-down morphant zebrafish larvae. Interestingly, 
the number and spatial arrangement of noradrenergic neurons in the locus coeruleus was 
similar in the morphant and control-injected larvae. However, the morphant larvae had 
reductions and disorganisation of posterior tuberculum DA neurons, a population that 
projects to the subpallium, a circuit hypothesised to be similar to the ascending 
dopaminergic pathways in mammals (45).  It is possible, therefore, that atomoxetine exerts 
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its effects on zebrafish behaviour in a similar manner to that observed in mammals, but this 
requires further exploration.  
 
Methylphenidate, a non-selective dopaminergic and noradrenergic reuptake inhibitor (46), 
has dose dependent therapeutic efficacy in human patients with ADHD (47). The effects of 
methylphenidate on impulsivity in animal models are somewhat confusing, with some 
studies in rodents showing that methylphenidate decreases impulsivity at 10mg/kg (46), but 
others in rodents (36) and zebrafish (32) finding that this drug, even at relatively low doses 
(<5mg/kg), increased premature responses in a 5-choice serial reaction time task, 
suggesting reduced impulse control. It is possible that task-related variables (e.g., the use of 
variable vs fixed-time pre-stimulus intervals) may have been the reason for these 
discrepancies. An explanation for the differences between the effects on impulsivity 
between methylphenidate and atomoxetine relate to the action of the former on increasing, 
and the latter on decreasing, striatal dopamine levels (29). Here, we found that 
methylphenidate dose-dependently reduced motor peaks in the larvae. Comparative studies 
have failed to find mesencephalic dopamine neurons in zebrafish (48), thus confusing the 
picture further. It is possible that factors relating to the ontogeny of the dopamine system 
may explain differences between larval and adult responses to methylphenidate. This will 
require further examination to be clear. In particular, future studies may examine the 
effects on dopamine availability in the telencephalon following administration of 
methylphenidate in larvae and in adult zebrafish.  
 
We found a strong effect of mutation on motor peaks in disc1fh292/fh292 (null) mutants, with 
the mutation appearing to reduce the behaviour. disc1 codes for the Disrupted in 
Schizophrenia 1 protein, which is responsible for various cell-regulatory processes, including 
differentiation, proliferation, neuronal outgrowth and adhesion (as well as many more). 
Variants at this locus have been variously associated with the pathogenesis of schizophrenia 
(49) and Disc1-/- null mice show high levels of impulsivity (23). To our knowledge, ours is the 
first study that has examined phenotypes in juvenile disc1 mutants of any species as a 
potential marker for adult phenotypes. The reduction in impulsivity in our sample may be 
explained by species differences. While we found that zebrafish disc1 mutants are less 
impulsive than wild-type siblings, this is somewhat at odds with evidence from adults of 
other species. For example, disc1 zebrafish have abnormal brain development which 
appears to result from the mutation affecting the noncanonical Wnt singaling pathway, in 
particular in its role in the regulation of convergence during gastrulation (20). In mice, 
however, Disc1 acts through -catenin to increase neuronal proliferation during gestation 
(50). In zebrafish, the noncanonical Wnt pathway mediates normal neuronal migration, 
suggesting that this mutation might alter neural circuit formation. This may be the same in 
mice, but it is not clear how this affects behavioural responses. Finally, there is currently no 
evidence that disc1 adults show impulsivity, and this also would be an interesting area for 
future research.   
 
We found no differences in the pink1 mutant. pink1 codes for the PTEN-induced kinase 1 
protein, and mutations at this locus have been linked to the heritable, autosomal-recessive 
form of Parkinson’s disease (51). There is currently fairly limited evidence relating to the 
effects of this mutation on early behavioural markers in model species, although there is 
some evidence that adults with variants show increased impulsivity. For example, Kitada et 
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al. (52) found that numbers of dopaminergic neurons and levels of midbrain (striatal) 
dopamine and DA receptors are not significantly different in Pink1 −/− mice than in wild-type 
control siblings. However, in zebrafish with a morpholino oligo-induced knockdown of pink1, 
although there were no marked differences in the numbers of diencephalic dopamine 
neurons, their organisation and hodology was severely disrupted (21). In addition, these 
morphants showed abnormal locomotor activity, including reductions in swimming 
behaviour. Here, we found no such differences in the pink1-/- mutant, nor did we observe 
any differences in motor peaks in this line. In addition, recent work has uncovered the 
effects of this mutation on increasing reactive oxygen species (ROS) and decreasing 
antioxidant enzymes. This may suggest that the behavioural deficits observed later in 
development (adulthood) might be the result of oxidative stress, as opposed to trait 
differences throughout ontogeny.  
 
We found no differences in the achesb55/+, the heterozygotes of which were observed to 
have lower impulsivity as adults (18). This may suggest that reductions in impulsivity 
observed in adult ache+/- are reflective of neurophysiological or neuroanatomical changes 
later in brain ontogeny. Conversely, we found that the ache+/- had lower movement in terms 
of distance travelled, something that was not observed in the adults. It is plausible that the 
reduced distance travelled is indicative that the ache+/- are simply more cautious or ‘vigilant’ 
in their behaviour. While evidence that the ache+/- anticipatory responses were lower, we 
found no evidence for improved accuracy in this line, however, making this interpretation 
potentially problematic. Further research on the mechanisms of the decrease in motor 
impulsivity in ache+/- and the changes in the phenotype during brain ontogeny may 
elucidate the discrepancy between larval and adult motor behaviour. Finally, a drawback of 
our present study is that as the achesb55/sb55 mutation is homozygous lethal, we were only 
able to carry out observations on ache+/- in-cross larvae and compare this to ache+/+ wild-
type siblings. This meant that of our mutant larvae, only 66% would be heterozygous for the 
mutation. To control for this, we ensured that there were more ache+/- incrossed siblings in 
the sample than ache+/+; however, it is plausible that this inability to differentiate accurately 
masked any effect of the mutation. Sequencing all the larvae was beyond the scope of this 
study as it was a first-round validation, but this would be a potential improvement for the 
future. 
 
We observed a bimodal dose-response on locomotor peaks for the non-selective dopamine 
agonist apomorphine, with an increase in peaks at 7µM and 37µM. There were no effects of 
the drug on distance traveled. Apomorphine activates both DRD2 and, to a lesser extent, 
DRD1. DRD1 are generally postsynaptic, and are excitatory. DRD2 are both pre- and 
postsynaptic, and can be excitatory or inhibitory. The bimodal response to the apomorphine 
thus may have been the result of differential affinity of the drug to the DRD1 and DRD2, the 
location of the receptors (DRD2 autoreceptors, or DRD1 and DRD2 postsynaptic receptors) 
and the consequence of  receptor activation (i.e., inhibitory or excitatory). 
 
We found no effects of the DRD2/D3 antagonist, amisulpride on motor peaks or on distance 
travelled after both 90-seconds and 30-minutes incubation in the drug. This is somewhat at 
odds with previous work that showed that, in adult zebrafish at least, incubation in 1mg/L 
amisulpride for 30-mins increased the amount of freezing and the angular velocity of the 
fish. The differences may reflect that the dose used in our study was too low to cause a 
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change in locomotor behaviour. In humans, genetic variants at the DRD2 locus are related 
to behavioural inhibition and impulsivity (53).  However, rats high in trait impulsivity, as 
measured by the 5-choice serial reaction time task, have a reduction of DRD2/3 in the 
nucleus accumbens (26), a finding similar to humans with increased impulsivity (54). More 
recently the link between DA receptors and impulsivity has been further specified to be 
imbalanced between DRD2/3 receptors in the shell and core regions of the nucleus 
accumbens (55); therefore, is It is possible that systemic administration would not induce 
impulsivity. However, it is not currently clear if zebrafish have a region that is functionally 
homologous to the nucleus accumbens in mammals, in particular not the anatomical sub-
regions of the core and shell. It would be useful to examine functional heterogeneity of 
adult zebrafish DRD2/3 and impulsivity in this species as this would help to understand if the 
species was a suitable complementary model to mammals for looking at DRD2/3 
therapeutic pharmacology for impulsivity.  
 
We found that nicotine dose-dependently increased distance traveled, but not motor peaks. 
Nicotine increasing motor activity in zebrafish larvae is well established, and we replicated 
this finding here (25). Although nicotine increases impulsivity in mammals (28), we did not 
find any effects of nicotine on motor peaks in larval zebrafish. This is in line with our 
previous findings in adult zebrafish, that did not show increases in anticipatory responses in 
a 5-choice serial reaction time task (18). Nicotine-induced impulsivity in rats has been 
suggested either to be caused by a decrease in accuracy of time estimation or general 
increases in hyperactivity, both known effects of acute nicotine administration (56). We find 
here that although increases in activity are clear, there are no related increases in motor 
peaks. This might suggest that different mechanisms are responsible for zebrafish and 
mammalian impulsivity, but further research with nicotine and related agonists and 
antagonists would be required to elucidate. 
 
In summary, we have potentially found evidence for an early marker of adult trait 
behavioural differences in zebrafish larvae. This has wide-ranging implications not only for 
increasing throughput of studies, but also for refinement and reduction of adult fish use in 
in vivo research. It is important to state that we are not suggesting that this measure could 
replace adult measures, but it appears that this method of early screening of putative genes 
that are linked to impulsivity may have some merit. There are several drawbacks that need 
to be addressed. For example, currently although we can reduce baseline motor peaks 
pharmacologically with atomoxetine and methylphenidate, drugs that reduce impulsivity, 
we only saw induction of motor peaks pharmacologically with apomorphine given the 
current exposure time. It may be that our exposure time was not sufficient to induce 
locomotor peaks in the amisulpride and nicotine-treated larvae. For example, Irons and 
colleagues (57) demonstrated that dopaminergic drugs have different pharmacological peak 
effects dependent on duration of exposure in zebrafish larvae. It may be that if the larvae 
were incubated for longer, peaks would manifest. There is also evidence that the motor 
peak phenotype can be reduced (19), and as we have observed here in the disc1 line. 
Further work on the pharmacology will be essential if this assay is to be adopted in front-
line screening programmes, including in particular pharmacological rescue of phenotypes.   
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